List All Pancreatic Cancer Trials

Pancreatic Cancer

 

PEGPH20 for Stage IV Untreated Pancreatic Cancer (2687)
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Investigator: Sunil R. Hingorani, MD;   Conditions: Metastatic Pancreatic Cancer;    Status: Closed;   Study ID: NCT01839487

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

Combination Chemotherapy w w/o PEGPH20 for Pancreatic Cancer (SWOG 1313)
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Investigator: Gabriela Chiorean, MD;   Conditions: Pancreatic Cancer;    Status: Pending;   Study ID: NCT01959139

Neoadjuvant Chemotherapy followed by Stereotactic Body Radiation Therapy with Algenpantucel-L Immunotherapy in Subjects for Pancreatic Cancer (20150183)
An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects with Borderline Resectable Pancreatic Cancer

Investigator: Gabriela Chiorean, MD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT02405585

Afatinib Dimaleate and Capecitabine for Solid Tumors, Pancreatic Cancer or Biliary Cancer (9078)
Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination with Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers

Investigator: Gabriela Chiorean. MD;   Conditions: Bile Duct Carcinoma, Recurrent Pancreatic Carcinoma, Solid Neoplasm, Stage III Pancreatic Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT02451553